Actinium Pharmaceuticals Therapeutic andOverview Pipeline Review H2 adds Exclusive Research on “Actinium Pharmaceuticals, Inc. – Product Pipeline Review – 2016” reports to its database.

Actinium Pharmaceuticals, Inc. – Product Pipeline Review – 2016

The report provides comprehensive information on the therapeutics under development by Actinium Pharmaceuticals, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.


Get Sample Report @


Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.



– The report provides a snapshot of the pipeline therapeutic landscape of Actinium Pharmaceuticals, Inc.

– The report provides overview of Actinium Pharmaceuticals, Inc. including its business description, key facts, and locations and subsidiaries

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report assesses Actinium Pharmaceuticals, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report features Actinium Pharmaceuticals, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects


Reasons to buy

– Evaluate Actinium Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline

– Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

– Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

– Identify and understand important and diverse types of therapeutics under development for Actinium Pharmaceuticals, Inc.

– Identify potential new clients or partners in the target demographic

– Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

– Devise corrective measures for pipeline projects by understanding Actinium Pharmaceuticals, Inc.’s pipeline depth and focus of pipeline therapeutics

– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Table of Content: Key Points

Table of Contents 2

List of Tables 4

List of Figures 4

Actinium Pharmaceuticals, Inc. Snapshot 5

Actinium Pharmaceuticals, Inc. Overview 5

Key Information 5

Key Facts 5

Actinium Pharmaceuticals, Inc. – Research and Development Overview 6

Key Therapeutic Areas 6

Actinium Pharmaceuticals, Inc. – Pipeline Review 10

Pipeline Products by Stage of Development 10

Pipeline Products – Monotherapy 11

Actinium Pharmaceuticals, Inc. – Pipeline Products Glance 12

Actinium Pharmaceuticals, Inc. – Late Stage Pipeline Products 12

Phase III Products/Combination Treatment Modalities 12

Actinium Pharmaceuticals, Inc. – Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Phase I Products/Combination Treatment Modalities 14

Actinium Pharmaceuticals, Inc. – Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

Actinium Pharmaceuticals, Inc. – Drug Profiles 16

Iomab-B 16

Product Description 16

Mechanism of Action 16

R&D Progress 16

Actimab-A 18

Product Description 18

Mechanism of Action 18

R&D Progress 18

BC-8Y90 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

BC-8SA 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

Actimab-B 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Actimab-Br 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Actimab-C 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Actimab-P 25



Access Report @                   


Get in touch:




Media Contact
Company Name:
Contact Person: Norah Trent
Phone: +1 646 845 9349, +44 208 133 9349
City: New York City
State: NY
Country: United States